NCT06545331 - Study of XB010 in Subjects With Solid Tumors | Biotech Hunter

Enrollment

396

Participants

Timeline

Start Date

August 6, 2024

Primary Completion Date

November 23, 2026

Study Completion Date

October 20, 2027

Conditions

Locally Advanced or Metastatic Solid TumorsEsophageal Squamous Cell CancerHead and Neck Squamous Cell CancerNSCLC (Non-small Cell Lung Cancer)Hormone-receptor-positive Breast CancerTriple Negative Breast Cancer (TNBC)

Interventions

DRUG

XB010

IV administration of XB010

DRUG

Pembrolizumab

IV administration of Pembrolizumab

Trial Locations (9)

22031

RECRUITING

Exelixis Clinical Site #2, Fairfax

28078

RECRUITING

Exelixis Clinical Site #3, Huntersville

37203

RECRUITING

Exelixis Clinical Site #9, Nashville

63110

RECRUITING

Exelixis Clinical Site #5, St Louis

73104

RECRUITING

Exelixis Clinical Site #6, Oklahoma City

74246

RECRUITING

Exelixis Clinical Site #7, Dallas

77030

RECRUITING

Exelixis Clinical Site #8, Houston

78758

RECRUITING

Exelixis Clinical Site #1, Austin

91010

RECRUITING

Exelixis Clinical Site #4, Duarte